Integrative Treatment Match Test

A Comprehensive Cancer Treatment Response & Monitoring Panel

Integrative Treatment Match Test

At Stem Cell Center Malaysia, we believe cancer care should be as personalised as possible because different cancers respond differently to the same medications, supplements, and supportive therapies.

The Integrative Treatment Match Test is an advanced liquid biopsy that analyses cancer-related cells and signals found in blood, then provides a structured report showing how a patient’s cancer-related profile may respond (sensitivity vs resistance patterns) to a broad range of treatment categories—covering conventional anti-cancer drugs, selected targeted therapies, and natural substances, together with gene expression information and circulating tumour cell (CTC) tracking.

This test is designed to support doctor–patient decision-making and treatment planning. It does not replace oncology care, imaging, biopsy, or your oncologist’s treatment decisions.

Why this matters in cancer

Cancer is not one single “uniform disease.” Even when two people have the same cancer diagnosis, the cancer cells can behave differently in terms of:

  • growth activity

  • resistance behaviour

  • response to certain medications

  • sensitivity to supportive / integrative options

  • recurrence or progression patterns over time

This is why treatment selection often involves trial-and-response. A structured test that provides response mapping can be useful as an added layer of insight, especially when a patient is:

  • deciding between treatment options

  • changing therapies

  • monitoring whether a plan is working over time

What is Integrative Treatment Match Test?

This panel combines several important components in one report:

1) Circulating Tumour Cells (CTC) Count

CTCs are cancer-related cells that may circulate in the bloodstream. The test measures CTC count to support understanding of cancer activity and treatment response over time (e.g., trend up or down).

Why this matters to patients:

  • It gives an additional monitoring signal that may be followed serially (when clinically appropriate).

  • It can support discussions about whether a treatment plan appears to be helping, alongside scans, tumour markers, symptoms, and clinical review.

2) Gene Expression and Cancer Activity Profiling

The test includes analysis of genetic / physiological expression patterns associated with how cancer-related cells behave and how they may respond to interventions.

In patient-friendly terms:
This looks at “how active” certain cancer-related biological pathways appear to be, which can support a more personalised strategy discussion.

3) Chemotherapeutic Agent Sensitivity / Resistance Mapping

The panel assesses response patterns across 50+ chemotherapeutic agents, providing sensitivity/resistance style categorisation to support treatment consideration.

What you receive in the report:

  • A structured list of drugs assessed in the panel

  • A response categorisation that helps guide discussion with your doctor

The reference framework groups effectiveness into tiers (e.g., below 30%, 31–80%, above 80%) as part of the sensitivity reporting approach.

Important: These are laboratory response categories, not guarantees of clinical outcomes in the body.

4) Natural Substances / Extract Response Mapping

Many natural compounds are being studied for supportive roles in cancer care, but responses can vary. The panel tests 50+ natural substances (example given includes curcumin) and reports which ones appear more relevant to the patient’s cancer-related profile.

What this means (simply):
Instead of “guessing” supplements, the test aims to provide a more structured, evidence-informed direction for discussion, under medical supervision.

5) Supportive Insight on Combined Modalities

The reference description notes that the panel can also provide insight related to heat and radiation treatments in combination with genetic information.

How to interpret this safely:
This is meant to support discussion with your oncology team where relevant. It is not a replacement for radiotherapy planning, staging, or oncology protocols.

Who this test may be suitable for?

This test may be considered (doctor review required) for patients who:

  • have a confirmed cancer diagnosis and are deciding between treatment options

  • wish to explore integrative oncology support in a more structured way

  • have recurrence, resistance, or multiple treatment pathways being considered

  • want an additional monitoring tool alongside standard care

  • prefer a more personalised discussion rather than a “one-size-fits-all” approach

The reference page also states it’s relevant for patients aiming to decide on the right treatment or monitor response.

  • What patients get at the end

    You receive a structured report that may include:

    • CTC count for activity/monitoring discussion

    • response mapping for 50+ chemotherapy agents

    • response mapping for 50+ natural substances

    • gene expression / activity-related profiling to support a personalised discussion

    We then schedule a medical review to help you understand:

    • what the results mean (and what they do not mean)

    • how it could fit into your oncology plan

    • what follow-up steps (if any) are reasonable to discuss with your oncologist